Johnson ແລະ Johnson
CEO Joaquin Duato’s warning earlier this month that the outlook for 2023 remains uncertain is tempering investor expectations ahead of the company’s earnings reports on Tuesday. It could also signal an end to big pharma’s status as a defensive stronghold.
Johnson ແລະ Johnson
(ticker: JNJ) is expected to report its fourth-quarter and full-year earnings before the market opens on Tuesday, and issue financial guidance for the 2023 fiscal year.
Source: https://www.barrons.com/articles/jnj-johnson-earnings-stock-price-51674485969?siteid=yhoof2&yptr=yahoo